Apalutamide radio-sensitisation of prostate cancer.

ABSTRACT:

Introduction

The combination of radiotherapy with bicalutamide is the standard treatment of prostate cancer patients with high-risk or locally advanced disease. Whether new-generation anti-androgens, like apalutamide, can improve the radio-curability of these patients is an emerging challenge.

Materials and methods

We comparatively examined the radio-sensitising activity of apalutamide and bicalutamide in hormone-sensitive (22Rv1) and hormone-resistant (PC3, DU145) prostate cancer cell lines. Experiments with xenografts were performed for the 22Rv1 cell line.

Results

Radiation dose-response viability and clonogenic assays showed that apalutamide had a stronger radio-sensitising activity for all three cell lines. Confocal imaging for γΗ2Αx showed similar DNA double-str

SUBMITTER: Kakouratos C 

PROVIDER: S-EPMC8575888 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature